|
**Overview**: Lung Cancer 12 Gene PDL1 Ventana Panel**Introduction**: The Lung Cancer 12 Gene PDL1 Ventana Panel is a diagnostic tool designed to assess lung cancer mutations and PDL1 using FFPE tissue. In India, lung cancer is the leading cause of cancer deaths (~70,000-80,000 new cases/year), with non-small cell lung cancer (NSCLC) ~85 percent, where EGFR, ALK, ROS1, KRAS, BRAF, MET, etc. mutations (~40-50 percent in adenocarcinoma) predict response to TKIs, and PD-L1 expression (Ventana SP263) guides pembrolizumab. High morbidity from under-testing in rural/low-SES smokers/nonsmokers with cough/hemoptysis, limited molecular/IHC labs, delayed targeted therapy/immunotherapy leading to progression or poor survival. Per oncology practices aligned with ICMR and Indian Society of Medical Oncology guidelines, the test employs PCR for 12-gene panel and IHC for PD-L1 Ventana SP263 over 1-2 days with high accuracy, valuable for precision therapy in advanced NSCLC. This diagnostic falls under cancer screening and targets patients with NSCLC (adenocarcinoma predominant), addressing accurate detection to guide osimertinib, crizotinib, or immunotherapy. With elevated morbidity due to underdiagnosis, the test supports public health efforts by enabling precise biomarker profiling and improving lung cancer outcomes. Its FFPE-based approach ensures reliable mutation and expression analysis.**Other Names**: Lung 12 Gene Pnl.**FDA Status**: FDA approved, CLIA certified for molecular pathology/histopathology/oncology, compliant with 2025 standards.**Historical Milestone**: Multi-gene + PD-L1 panel standard since 2010s; in India, expanding in precision oncology.**Purpose**: The test assesses 2 parameters including 12-gene panel to guide lung cancer assessment, detect actionable mutations/PD-L1, inform targeted/immunotherapy.**Test Parameters**: 1. 12-Gene Panel, 2. PDL1 Ventana SP263.**Pretest Condition**: No fasting required; patients should have lung biopsy.**Specimen**: Formalin-fixed paraffin-embedded block (0.5â€"2 cm³), transported within specified times to maintain sample integrity.Sample Stability: Indefinite when properly stored in formalin/paraffin; testing possible long-term.**Medical History**: Patients should provide details on smoking, symptoms, stage.**Consent**: Written informed consent is required, detailing the test's purpose, potential risks of undetected mutation/PD-L1 including wrong therapy, benefits of profiling, and no additional discomfort (uses existing block).**Procedural Considerations**: The test involves sample processing using PCR/IHC by trained personnel to ensure accurate scoring, avoid artifacts, and provide detailed report within 1-2 days using provided controls. Laboratories must maintain a controlled environment, adhere to quality assurance protocols.**Factors Affecting Result Accuracy**: Poor block quality, inadequate tumor content, or interpretation differences can affect results. Correlation with clinical evaluation or additional testing is recommended to confirm findings.**Clinical Significance**: EGFR/ALK positive or PD-L1 high indicates targeted/immunotherapy eligibility, necessitating specialist input.**Specialist Consultation**: Medical oncologists/thoracic oncologists should be consulted for management.**Additional Supporting Tests**: NGS, full biomarker panel for confirmation.**Test Limitations**: 12-gene limited; comprehensive approach required.**References**: Indian Journal of Medical Oncology 2024, Lung Cancer Studies India 2023. |
